Patents by Inventor Kevin McDonnell
Kevin McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160222111Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 30, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222110Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 29, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222109Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 29, 2015Publication date: August 4, 2016Applicants: Dyax Corp., Biogen Hemophilia Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222108Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 22, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160194397Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 31, 2015Publication date: July 7, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160122394Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.Type: ApplicationFiled: June 18, 2014Publication date: May 5, 2016Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard S. BLUMBERG, Timo RATH, Kristi BAKER, Adam MEZO, Zachary TAYLOR, Kevin MCDONNELL, Rosa Maria Silva Garcia GRENHA
-
Patent number: 9260520Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: January 30, 2014Date of Patent: February 16, 2016Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20150354662Abstract: A shock absorbing system for impact energy dissipation employs removable unitary cells of compressible members in communication with a reservoir and containing a first working fluid. Resilient structural members may be placed intermediate the compressible members to deform responsive to compression to provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state.Type: ApplicationFiled: August 21, 2015Publication date: December 10, 2015Inventor: Kevin McDonnell
-
Patent number: 9055782Abstract: A shoe structure for foot strike energy dissipation employs compressible members each having an internal void containing a first working fluid. A set of mating compressible members are each connected to a related one of the first compressible members through a fluid conduit such that the first working fluid is transferred from the related compressible member to the mating compressible member responsive to compression induced by foot strike. Resilient structural members are placed intermediate the compressible members to deform responsive to compression of the foot bed induced by foot strike provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state. A cavity contains a second working fluid that is transmissible between the compressible members responsive to compression of the foot bed. Cooling tubes are provided for energy dissipation of the second working fluid which bathes the compressible members, conduits and resilient elements.Type: GrantFiled: October 24, 2008Date of Patent: June 16, 2015Inventor: Kevin McDonnell
-
Patent number: 9012603Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: December 18, 2009Date of Patent: April 21, 2015Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Patent number: 8906844Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: GrantFiled: August 1, 2008Date of Patent: December 9, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Publication number: 20140248287Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: January 30, 2014Publication date: September 4, 2014Applicants: SYNTONIX PHARMACEUTICALS, INC., DYAX CORP.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Patent number: 8815246Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: September 14, 2012Date of Patent: August 26, 2014Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Patent number: 8635238Abstract: An inventory stock ledger system, apparatus and method including a process by which one can track inventory efficiently, but can also utilize to perform inventory analysis on a dynamic level. The method includes recording inventory snapshots across various dimensions of a retail business and tracking the inventory levels for select products in to provide real time reports. Central to the apparatus is the idea that inventory can be viewed from a central starting point, and then examined among various dimensions. Inventory management is readily modified and dynamic. The method includes a build capability for examining the inventory levels and snapshots of inventory for a retail market franchise.Type: GrantFiled: January 11, 2010Date of Patent: January 21, 2014Assignee: Fairway Group Acquisition CompanyInventors: Arthur Tisi, Kevin McDonnell, Oleg Margolin, Oleg Alshansky
-
Publication number: 20130078262Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: Dyax Corp.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
-
Publication number: 20130045218Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: August 13, 2012Publication date: February 21, 2013Applicants: Syntonix Pharmaceuticals, Inc., Dyax Corp.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
-
Patent number: 8273351Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: April 24, 2009Date of Patent: September 25, 2012Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
-
Publication number: 20120048663Abstract: A shock absorbing system for impact energy dissipation employs compressible members each having an internal void containing a first working fluid. At least one accumulator is connected to the compressible members through a fluid conduit such that the first working fluid is transferred from the compressible member to the accumulator responsive to compression induced by an impact. A pad and a liner intermediately constrain the compressible members. Resilient structural members are placed intermediate the compressible members to deform responsive to compression of the foot bed induced by foot strike provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state.Type: ApplicationFiled: October 28, 2011Publication date: March 1, 2012Inventor: Kevin McDonnell
-
Publication number: 20120021484Abstract: The invention is directed to methods of purifying Fc-containing molecules using a soluble neonatal Fc receptor (sFcRn). Native FcRn binds Fc-containing proteins at or below about pH 6.5 and releases them at or above about pH 7 and provides a much milder approach for capturing and purifying Fc-containing proteins, in particular, therapeutic Fc-containing proteins. Other embodiments of the invention provide modifications to alter the pH for binding and elution to the sFcRn, to modulate Fc-containing protein binding affinity, to affect sFcRn linkage to a support surface, or to improve the stability of sFcRn to conditions utilized in the methods of the invention.Type: ApplicationFiled: October 21, 2009Publication date: January 26, 2012Applicant: Biogen Idec MA Inc.Inventor: Kevin A. McDonnell
-
Patent number: 8101186Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: February 16, 2007Date of Patent: January 24, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro